Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980372 | 0.86 | ADORA1 (0.39) | SMN1; SMN2USP2NR1H2HPGDALDH1A1 | |
| SCHEMBL19331906 | 0.86 | HPGD (0.38) | SMN1; SMN2USP2EPHX2EPHX1CNR2 | |
| SCHEMBL5216557 | 0.85 | USP2 (0.44) | SMN1; SMN2USP2EPHX2EPHX1CNR2 | |
| SCHEMBL20826636 | 0.83 | USP2 (0.40) | SMN1; SMN2USP2NR1H2EPHX2EPHX1 | |
| SCHEMBL30352914 | 0.82 | USP2 (0.42) | SMN1; SMN2USP2NR1H2EPHX2EPHX1 | |
| SCHEMBL30722401 | 0.82 | USP2 (0.37) | SMN1; SMN2USP2NR1H2EPHX2EPHX1 | |
| SCHEMBL23537963 | 0.80 | USP2 (0.43) | SMN1; SMN2USP2NR1H2EPHX2EPHX1 | |
| SCHEMBL27225356 | 0.80 | USP2 (0.43) | SMN1; SMN2USP2NR1H2EPHX2EPHX1 | |
| SCHEMBL12439836 | 0.80 | NR1H2 (0.45) | SMN1; SMN2USP2NR1H2EPHX2EPHX1 | |
| SCHEMBL31748061 | 0.80 | USP2 (0.38) | SMN1; SMN2USP2NR1H2EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556883-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-02-11 | — | — | US | disclosed |
| US-10556883-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-02-11 | — | — | US | disclosed |
| EP-3199534-B1 | BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2018-09-05 | — | — | EP | disclosed |
| US-9777020-B2 | Furo-3-carboxamide derivatives and methods of use | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170247353-A1 | BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-31 | — | — | US | disclosed |
| US-20170247353-A1 | BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-31 | — | — | US | disclosed |
| US-20170247353-A1 | BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-31 | — | — | US | disclosed |
| EP-3199534-A1 | BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2017-08-02 | — | — | EP | disclosed |
| EP-3199534-A1 | BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2017-08-02 | — | — | EP | disclosed |
| EP-3097095-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556883-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics | TST, ARSA, TYR | SMN1; SMN2 2204/4885USP2 2533/4885NR1H2 1007/4885 |
| US-20170247353-A1 | BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AND COSMETICS | TST, ARSA, TYR | SMN1; SMN2 2204/4885USP2 2533/4885NR1H2 1007/4885 |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | SMN1; SMN2 3099/4885USP2 1176/4885NR1H2 945/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | SMN1; SMN2 3099/4885USP2 1176/4885NR1H2 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.